Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice

Effective treatment of glioma still stands as a challenge in medical science. The work aims for the fabrication and evaluation of lipid based nanostructures for improved delivery of lomustine to brain tumor cells. Experimental formulations (LNLs) were developed by modified lipid layer hydration technique and evaluated for different in vitro characteristics like particle size analysis, surface charge, surface morphology, internal structure, in vitro drug loading, drug release profile etc. Anticancer potential of selected LNLs was tested in vitro on C6 glioma cell line. Electron microscopic study depicted a size of less than 50 nm for the selected LNLs along wirh 8.8% drug loading with a sustained drug release tendency over 48 h study period. Confocal microscopy revealed resonable internalization of the selected LNL in C6 cells. LNLs were found more cytotoxic than free drug and blank nanocarriers as depicted from MTT assay. The selected LNL showed improved pharmacokinetic profile both in blood and brain in the experimental mice models along with negligible hemolysis in mice blood cells. Further studies are warranted for the future translation of LNLs at clinics.

99mTc-Anionic Linear Globular Dendrimer-G2-Phenylalanine Conjugate: Novel Brain Tumor SPECT Imaging

The purpose of this study was the investigation of the targeting potential of 99mTc-Labeled dendrimer-phenylalanine conjugate for brain tumor SPECT imaging. L-Type amino acid transporters (LAT1) are highly expressed in the blood-brain barrier as well as in brain cancer cells; thus, targeting LAT1 using phenylalanine could improve the sensitivity and specificity of radiosynthesis nanocarrier. In this study, the dendrimer G2–phenylalanine conjugate was synthesized and characterized by Fourier transform infrared spectroscopy, atomic force microscopy, particle size, and zeta potential. MTT assay was done for cell viability measurement in different concentrations of nanoparticles (0.125, 0.25, 0.5 mg/ml) on C6 glioma cell lines; the uptake study was evaluated using fluorescence-activated cell sorter (FACS) instrument; finally, SPECT scintigraphy in glioma tumor-bearing Wistar rats was done. The dendrimer-phenylalanine conjugate particle size was found in the range of 74.14±2.2 to 109±3.1 nm, with a slightly negative surface charge. Also, phenylalanine present on the dendrimer's surface–phenylalanine conjugate enhanced the dendrimer's cellular uptake–phenylalanine conjugate on the C6 glioma cell line. Results of SPECT imaging and fluorescence studies revealed that dendrimer–phenylalanine conjugate accumulated into the brain tumor cells, and it can be suggested as a promising brain-targeting probe with no toxicity in brain tumor imaging.

Differentiation of Tumorigenic C6 Glioma Cells Induced by Enhanced IL-6 Signaling

Background and objectives: Cancer stem cells (CSCs) are obstacles to cancer therapy due to their therapeutic resistance, ability to initiate neoplasia, and roles in tumor relapse and metastasis. Efforts have been made to cure CSCs, such as the use of differentiation therapy, which induces cancer stem-like cells to undergo differentiation and decrease their tumorigenicity. Interleukin 6 (IL-6) upregulates the expression of glial fibrillary acidic protein (GFAP) in C6 glioma cells, indicating that it is able to induce the differentiation of these cells. The C6 glioma cell line forms a high percentage of cancer stem-like cells, leading us to speculate whether IL-6 signaling could modulate the differentiation of tumorigenic C6 glioma cells. However, we observed that IL-6 alone could not efficiently induce the differentiation of these cells. Therefore, different IL-6 signaling elicitors, including IL-6 alone, a combination of IL-6 and soluble IL-6 receptor (IL-6/sIL-6R), and tumor necrosis factor-α (TNF-α) plus IL-6/sIL-6R (TNF-α/IL-6/sIL-6R), were evaluated for their potential use in differentiation therapy. Materials and Methods: The potential of IL-6 signaling elicitors in differentiation therapy were examined by assessing changes in biomarker levels, the rate of cell proliferation, and tumorigenicity, respectively. Results: Enhanced IL-6 signaling could effectively induce C6 glioma cell differentiation, as determined by observed variations in the expression of differentiation, cell cycle, and stem cell biomarkers. Additionally, the total cell population and the tumorigenicity of glioma cells were all considerably reduced after TNF-α/IL-6/sIL-6R treatment. Conclusions: Our findings provide evidence that enhanced IL-6 signaling can efficiently promote tumorigenic C6 glioma cells to undergo differentiation.